Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Upfront Surgery Alone for Resectable or Borderline Resectable Pancreatic Cancer." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432274/all/images/closex.png. Accessed 15 May 2024.
Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432274/all/images/closex.png. Accessed May 15, 2024.
Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/432274/all/images/closex.png
Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Upfront Surgery Alone for Resectable or Borderline Resectable Pancreatic Cancer [Internet]. In: Cochrane Abstracts. [cited 2024 May 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432274/all/images/closex.png.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer
ID - 432274
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432274/all/images/closex.png
DB - Evidence Central
DP - Unbound Medicine
ER -